Technical Analysis for LYEL - Lyell Immunopharma, Inc.

Grade Last Price % Change Price Change
C 14.45 4.79% 0.66
LYEL closed up 4.79 percent on Monday, October 25, 2021, on 27 percent of normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent N/A Up Up
Historical LYEL trend table...

Date Alert Name Type % Chg
Crossed Above 50 DMA Bullish 0.00%
MACD Bullish Centerline Cross Bullish 0.00%
Overbought Stochastic Strength 0.00%
Narrow Range Bar Range Contraction 4.79%
NR7 Range Contraction 4.79%
Stochastic Reached Overbought Strength 4.79%
Weak + Overbought Other 4.79%
Weak, Overbought and Reversal Signs Reversal 4.79%
Overbought Stochastic Strength 4.79%
Narrow Range Bar Range Contraction 4.11%
Older End-of-Day Signals for LYEL ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
50 DMA Resistance about 19 hours ago
60 Minute Opening Range Breakout about 19 hours ago
Rose Above 50 DMA about 19 hours ago
Up 3% about 19 hours ago
Up 2% about 19 hours ago
View Earlier Intraday Alerts

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Lyell Immunopharma, Inc. Description

Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate population of T cells with durable stemness. Its pipeline includes LYL797, a T cell product candidate for the treatment of non-small cell lung cancer and triple negative breast cancers, as well as ovarian and other solid tumors; LYL845, an IV administered autologous TIL therapy for multiple solid tumors; and NY-ESO-1, a T cell product candidate for synovial sarcoma and other solid tumor indications. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California with additional offices in Seattle and Bothell, Washington.


Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Cancer Life Sciences Biology Solid Tumors Non Small Cell Lung Cancer Cell Biology Treatment Of Non Small Cell Lung Cancer Solid Tumor Cloning Induced Stem Cells Stem Cell Developmental Biology Synovial Sarcoma

Is LYEL a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 19.84
52 Week Low 10.62
Average Volume 474,632
200-Day Moving Average 0.00
50-Day Moving Average 14.10
20-Day Moving Average 13.35
10-Day Moving Average 13.58
Average True Range 1.04
ADX 14.79
+DI 27.04
-DI 16.84
Chandelier Exit (Long, 3 ATRs) 11.90
Chandelier Exit (Short, 3 ATRs) 14.23
Upper Bollinger Bands 15.01
Lower Bollinger Band 11.68
Percent B (%b) 0.83
BandWidth 24.96
MACD Line 0.05
MACD Signal Line -0.18
MACD Histogram 0.2343
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 15.67
Resistance 3 (R3) 15.54 15.01 15.46
Resistance 2 (R2) 15.01 14.70 15.07 15.39
Resistance 1 (R1) 14.73 14.51 14.87 14.86 15.33
Pivot Point 14.20 14.20 14.27 14.26 14.20
Support 1 (S1) 13.92 13.89 14.06 14.05 13.57
Support 2 (S2) 13.39 13.70 13.45 13.51
Support 3 (S3) 13.11 13.39 13.44
Support 4 (S4) 13.24